Occam Places Emile Nuwaysir as CEO of Ensoma
Ensoma, a 5AM/F-Prime investment, is an in vivo gene editing platform company precisely engineering any or all hematopoietic and immune cells for a one-time, off-the-shelf treatment for a range of debilitating diseases.
In late 2021, Occam recruited Emile Nuwaysir, PhD, as the company’s first CEO. Previously, Emile served as CEO of BlueRock Therapeutics which was acquired by Bayer in 2019 for $1B.
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.